Why the study?
Do TNFi biologics reduce discontinuation rates compared to non-TNFi biologics in patients with rheumatoid arthritis?
Do TNFi biologics reduce discontinuation rates compared to non-TNFi biologics in patients with rheumatoid arthritis?
Patients with rheumatoid arthritis tend to remain on their first and second biologics for relatively long periods, with lower discontinuation rates observed for TNFi compared to non-TNFi biologics.
No takes yet. Share an insight, caveat, or question.
May support TNFi preference for persistence in RA; observational data leaves open need for RCT confirmation.
Ghorayeb et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: